LeMaitre Q1 sales rise 12% to $59.9 million; 2025 sales guidance raised to $245 million
LeMaitre Vascular reported first-quarter 2025 net sales of $59.9 million, up 12% from a year earlier, and diluted earnings per share of $0.48, up from $0.44. The company raised its full-year 2025 sales guidance to $242 million to $249 million, from a prior $239 million, which gives shareholders a higher revenue outlook.
Key points
- Q1 2025 net sales $59.9 million, up 12% (13% organic); gross margin 69.2%, up 60 basis points
- Diluted EPS $0.48 vs. $0.44 a year earlier; income from operations $12.6 million, up 6%
- Full-year 2025 sales guidance $242 million to $249 million, up from prior $239 million; Q2 sales guidance $61.5 million to $63.5 million
- Quarterly dividend of $0.20 per share, payable May 29, 2025 to holders of record on May 15, 2025
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.